FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an immune effector cell modified by engineering methods for expression of a chimeric antigen receptor (hereinafter – CAR), containing Tet2 inhibitor and Tet2 gene disorder, to its production method, as well as to a composition containing it, and a population. A method for increasing therapeutic efficiency of an immune effector cell is also disclosed, including a stage of bringing the specified immune effector cell into contact with Tet2 inhibitor. The invention also relates to a vector containing a sequence encoding CAR and a sequence encoding Tet2 inhibitor.
EFFECT: invention is effective for the treatment of a disease associated with the expression of a tumor antigen in an individual.
44 cl, 32 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
| COMPOSITIONS AND METHODS OF TREATING HEMOGLOBINOPATHIES | 2016 |
|
RU2812491C2 |
